These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 31221204)

  • 21. Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade.
    Wilkinson RW; Leishman AJ
    Front Immunol; 2018; 9():1082. PubMed ID: 29910800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Managing immune dysregulation resulting from immune checkpoint inhibitors: impact of the ASCO guidelines and key take-homes for immunologists.
    Kim ST; Suarez-Almazor ME
    Expert Rev Clin Immunol; 2019 Mar; 15(3):211-213. PubMed ID: 30589372
    [No Abstract]   [Full Text] [Related]  

  • 23. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The "immune checkpoints", how does it work].
    Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
    Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A tumor multicomponent targeting chemoimmune drug delivery system for reprograming the tumor microenvironment and personalized cancer therapy.
    Sau S; Tatiparti K; Alsaab HO; Kashaw SK; Iyer AK
    Drug Discov Today; 2018 Jul; 23(7):1344-1356. PubMed ID: 29551455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent progress in therapeutic antibodies for cancer immunotherapy.
    Lee A; Sun S; Sandler A; Hoang T
    Curr Opin Chem Biol; 2018 Jun; 44():56-65. PubMed ID: 29885949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Equibalancing immune-related adverse events and anticancer activity of immune checkpoint inhibitors.
    Seeruttun SR
    Thorac Cancer; 2019 Oct; 10(10):1855-1856. PubMed ID: 31456312
    [No Abstract]   [Full Text] [Related]  

  • 28. The immunopathogenesis of rheumatic immune adverse events from checkpoint inhibitors: prospects for targeted therapy.
    Calabrese LH; Calabrese C
    Curr Opin Rheumatol; 2020 Mar; 32(2):175-183. PubMed ID: 31922970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sarcoidosis, malignancy and immune checkpoint blockade.
    Gaughan EM
    Immunotherapy; 2017 Oct; 9(13):1051-1053. PubMed ID: 29032735
    [No Abstract]   [Full Text] [Related]  

  • 30. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
    Conforti F; Pala L; Bagnardi V; De Pas T; Martinetti M; Viale G; Gelber RD; Goldhirsch A
    Lancet Oncol; 2018 Jun; 19(6):737-746. PubMed ID: 29778737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The paired receptors TIGIT and DNAM-1 as targets for therapeutic antibodies.
    Stein N; Tsukerman P; Mandelboim O
    Hum Antibodies; 2017; 25(3-4):111-119. PubMed ID: 28035916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary.
    Brahmer JR; Lacchetti C; Thompson JA
    J Oncol Pract; 2018 Apr; 14(4):247-249. PubMed ID: 29517954
    [No Abstract]   [Full Text] [Related]  

  • 34. Immune checkpoint inhibitors and cardiovascular toxicity.
    Lyon AR; Yousaf N; Battisti NML; Moslehi J; Larkin J
    Lancet Oncol; 2018 Sep; 19(9):e447-e458. PubMed ID: 30191849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.
    Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ
    J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of challenging immune-related gastrointestinal adverse events associated with immune checkpoint inhibitors.
    Hamamoto Y; Shin N; Hoshino T; Kanai T
    Future Oncol; 2018 Dec; 14(30):3187-3198. PubMed ID: 30188189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Landscape of Immune-Related Pneumonitis in Cancer Patients with Asthma Being Treated with Immune Checkpoint Blockade.
    Galant-Swafford J; Troesch A; Tran L; Weaver A; Doherty TA; Patel SP
    Oncology; 2020; 98(2):123-130. PubMed ID: 31665718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody engineers seek optimal drug targeting TIGIT checkpoint.
    Dolgin E
    Nat Biotechnol; 2020 Sep; 38(9):1007-1009. PubMed ID: 32887966
    [No Abstract]   [Full Text] [Related]  

  • 39. Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings.
    Wang GX; Kurra V; Gainor JF; Sullivan RJ; Flaherty KT; Lee SI; Fintelmann FJ
    Radiographics; 2017; 37(7):2132-2144. PubMed ID: 29131763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Introduction.
    Liu J; Xu J
    Adv Exp Med Biol; 2020; 1248():1-6. PubMed ID: 32185704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.